TY - JOUR
T1 - Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan
AU - Toft, Anders
AU - Urup, Thomas
AU - Christensen, Ib Jarle
AU - Michaelsen, Signe Regner
AU - Lukram, Babloo
AU - Grunnet, Kirsten
AU - Larsen, Vibeke Andrée
AU - Lassen, Ulrik
AU - Broholm, Helle
AU - Poulsen, Hans Skovgaard
PY - 2018
Y1 - 2018
N2 - Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.
AB - Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.
KW - Journal Article
U2 - 10.1080/07357907.2018.1430818
DO - 10.1080/07357907.2018.1430818
M3 - Journal article
C2 - 29393706
SN - 0735-7907
VL - 36
SP - 165
EP - 174
JO - Cancer Investigation
JF - Cancer Investigation
IS - 2
ER -